Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06097468 · ClinicalTrials.gov registry record · Phase 1
Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)
A Phase 1 study of Oral Cavity Squamous Cell Carcinoma, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06097468 is a Phase 1 study of Oral Cavity Squamous Cell Carcinoma that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 40 participants, below the 134-participant average among 8 other Oral Cavity Squamous Cell Carcinoma trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06097468, a Phase 1 study of Oral Cavity Squamous Cell Carcinoma, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study of oral nisin administration in patients with OSCC who are undergoing complete surgical resection surgery with or without adjuvant radiation/chemoradiation as part of their routine care at the University of California, San Francisco (UCSF).
Conditions Studied
Interventions
- DRUG NisinZ® P
- PROCEDURE Surgery (non-interventional, standard of care)
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-02-02 |
| Est. Completion | 2027-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06097468
The ClinicalTrials.gov registry entry for NCT06097468 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 134-participant average among 8 other Oral Cavity Squamous Cell Carcinoma trials with a reported enrollment target (70% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Oral Cavity Squamous Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which NisinZ® P is the first listed.
NCT06097468 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06097468 about?
NCT06097468 is a clinical study titled "Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)". This is a study of oral nisin administration in patients with OSCC who are undergoing complete surgical resection surgery with or without adjuvant radiation/chemoradiation as part of their routine care at the University of California, San Francisco (UCSF).
What is the current status of trial NCT06097468?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2024-02-02. Estimated completion is 2027-09-01.
What conditions does trial NCT06097468 study?
This clinical trial studies the following conditions: Oral Cavity Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06097468?
The interventions under investigation include: NisinZ® P (DRUG), Surgery (non-interventional, standard of care) (PROCEDURE).
Who is sponsoring clinical trial NCT06097468?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06097468 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oral Cavity Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
RECRUITING · Phase 2
-
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
RECRUITING · Phase 2
-
Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial
RECRUITING · Phase 2
-
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RECRUITING · Phase 2
-
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
RECRUITING · Phase 2
-
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.